cartilage-derived inhibitor

cartilage-derived inhibitor

Fringe oncology
An angiogenic macroprotein abundant in shark cartilage, which allegedly decreased tumour formation in sharks.
 
Molecular medicine
A natural anti-angiogenesis factor for treating solid tumours, which was being developed in the mid-1990s by Boston Life Sciences. The data on the efficacy of cartilage proved compellingly underwhelming enough that all work on developing such products for treating cancer was abandoned.
References in periodicals archive ?
BLSI's products in pre-clinical development or in clinical trials include, among others, THERAFECTIN(R) (amiprilose HCl), a potential treatment for rheumatoid arthritis; Cartilage-derived Inhibitor (CDI), a natural anti-angiogenesis factor to treat solid tumors; Axogenesis Factor 1 (AF-1), a novel central nervous system growth factor; and transcription factors that control the expression of molecules associated with autoimmune disease and allergies.
BLSI's products in clinical trials or in pre-clinical development include Cartilage-derived Inhibitor (CDI), a natural anti-angiogenesis factor for the treatment of solid tumors; Axogenesis Factor 1 (AF-1), a novel central nervous system growth factor; Altropane(TM), a radioimaging agent for the diagnosis of Parkinson's Disease; THERAFECTIN(R) for the treatment of Rheumatoid Arthritis; and a different transcription factor that controls the expression of molecules associated with autoimmune disease.
BLSI's products include, among others, THERAFECTIN(R) (amiprilose HCl), a potential treatment for rheumatoid arthritis; Cartilage-Derived Inhibitor (CDI), a natural anti-angiogenesis factor for the treatment of solid tumors; Axogenesis Factor 1 (AF-1), a novel central nervous system growth factor; Altropane(TM), a radioimaging agent for the diagnosis of Parkinson's Disease; and a transcription factor that controls the expression of molecules associated with autoimmune disease.
In addition to THERAFECTIN, BLSI's products include Cartilage-derived Inhibitor (CDI), a natural anti-angiogenesis factor for the treatment of solid tumors; Axogenesis Factor 1 (AF-1), a novel central nervous system growth factor; Altropane(TM), a radioimaging agent for the diagnosis of Parkinson's Disease; and a transcription factor that controls the expression of molecules associated with autoimmune disease.
BLSI's products include, among others, THERAFECTIN(R) (amiprilose HCI), a potential treatment for rheumatoid arthritis; Cartilage-derived Inhibitor (CDI), a natural anti-angiogenesis factor for the treatment of solid tumors; Axogenesis Factor 1 (AF-1), a novel central nervous system growth factor; Altropane(TM), a radioimaging agent for the diagnosis of Parkinson's Disease; and a transcription factor that controls the expression of molecules associated with autoimmune disease.
BLSI's products include, among others, THERAFECTIN(R) (amiprilose HC1), a potential treatment for rheumatoid arthritis; Cartilage-Derived Inhibitor (CDI), a natural anti-angiogenesis factor to treat solid tumors; Axogenesis Factor 1 (AF-1), a novel central nervous system growth factor; and a transcription factor that controls the expression of molecules associated with autoimmune disease.
BLSI's products include among others, Cartilage-derived Inhibitor (CDI), a natural anti-angiogensis factor for the treatment of solid tumors; Axogenesis Factor 1 (AF-1), a novel central nervous system growth factor; Altropane(TM), a radioimaging agent for the diagnosis of Parkinson's Disease; and a transcription factor that controls the expression of molecules associated with autoimmune disease.
Full browser ?